Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGT121.414.LS +/- VRC07-523LS in Healthy Adults
NCT04212091Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PGT121 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness at Day 224, Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration at Day 224 and 6 more. Started Nov 2020; status: completed.
02
Drugs
PGT121
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04212091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04212091.